...
search icon
urgn-img

UroGen Pharma Ltd Share Price

URGN
NMQ
$20.1
-$0.11
(-0.54%)
1D
Industry: Biotechnology Sector: Health Care

UroGen Pharma Ltd Analyst Forecast

UroGen Pharma Ltd Share Price Chart

UroGen Pharma Ltd Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$946.01M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
792.48K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.36
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.42 L
$30 H
$20.1

About UroGen Pharma Ltd, Common Stock

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. more

Industry: BiotechnologySector: Health Care

UroGen Pharma Ltd Stock Returns

Time FrameURGNSectorS&P500
1-Week Return-5.85%-1.08%-1.38%
1-Month Return1.36%-0.47%-1.81%
3-Month Return-15.97%2.13%1.38%
6-Month Return-0.05%17.04%5.68%
1-Year Return90.7%6.56%11.74%
3-Year Return112.47%16.78%65.15%
5-Year Return-25.33%34.34%73.68%
10-Year Return43.78%137.88%260.03%

UroGen Pharma Ltd Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue11.80M48.04M64.36M82.71M90.40M[{"date":"2020-12-31","value":13.05,"profit":true},{"date":"2021-12-31","value":53.14,"profit":true},{"date":"2022-12-31","value":71.19,"profit":true},{"date":"2023-12-31","value":91.5,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue1.01M5.16M7.65M9.36M8.88M[{"date":"2020-12-31","value":10.78,"profit":true},{"date":"2021-12-31","value":55.09,"profit":true},{"date":"2022-12-31","value":81.76,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":94.87,"profit":true}]
Gross Profit10.79M42.88M56.70M73.35M81.52M[{"date":"2020-12-31","value":13.24,"profit":true},{"date":"2021-12-31","value":52.61,"profit":true},{"date":"2022-12-31","value":69.56,"profit":true},{"date":"2023-12-31","value":89.98,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin91.45%89.27%88.11%88.68%90.18%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.61,"profit":true},{"date":"2022-12-31","value":96.35,"profit":true},{"date":"2023-12-31","value":96.98,"profit":true},{"date":"2024-12-31","value":98.61,"profit":true}]
Operating Expenses137.53M135.18M135.74M138.89M178.30M[{"date":"2020-12-31","value":77.13,"profit":true},{"date":"2021-12-31","value":75.81,"profit":true},{"date":"2022-12-31","value":76.13,"profit":true},{"date":"2023-12-31","value":77.9,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(126.74M)(92.29M)(79.04M)(65.54M)(96.78M)[{"date":"2020-12-31","value":-12673900000,"profit":false},{"date":"2021-12-31","value":-9229200000,"profit":false},{"date":"2022-12-31","value":-7904100000,"profit":false},{"date":"2023-12-31","value":-6553600000,"profit":false},{"date":"2024-12-31","value":-9678200000,"profit":false}]
Total Non-Operating Income/Expense3.26M(16.87M)(36.41M)(44.68M)(30.88M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-517.71,"profit":false},{"date":"2022-12-31","value":-1117.71,"profit":false},{"date":"2023-12-31","value":-1371.52,"profit":false},{"date":"2024-12-31","value":-947.82,"profit":false}]
Pre-Tax Income(125.11M)(109.37M)(108.03M)(98.32M)(124.04M)[{"date":"2020-12-31","value":-12511000000,"profit":false},{"date":"2021-12-31","value":-10937100000,"profit":false},{"date":"2022-12-31","value":-10802800000,"profit":false},{"date":"2023-12-31","value":-9832400000,"profit":false},{"date":"2024-12-31","value":-12404200000,"profit":false}]
Income Taxes3.37M1.45M1.75M3.92M2.83M[{"date":"2020-12-31","value":86.07,"profit":true},{"date":"2021-12-31","value":36.96,"profit":true},{"date":"2022-12-31","value":44.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":72.24,"profit":true}]
Income After Taxes(128.48M)(110.82M)(109.78M)(102.24M)(126.87M)[{"date":"2020-12-31","value":-12848400000,"profit":false},{"date":"2021-12-31","value":-11082000000,"profit":false},{"date":"2022-12-31","value":-10978300000,"profit":false},{"date":"2023-12-31","value":-10224400000,"profit":false},{"date":"2024-12-31","value":-12687400000,"profit":false}]
Income From Continuous Operations(128.48M)(110.82M)(109.78M)(105.10M)(126.87M)[{"date":"2020-12-31","value":-12848400000,"profit":false},{"date":"2021-12-31","value":-11082000000,"profit":false},{"date":"2022-12-31","value":-10978300000,"profit":false},{"date":"2023-12-31","value":-10509700000,"profit":false},{"date":"2024-12-31","value":-12687400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(128.48M)(110.82M)(109.78M)(102.24M)(126.87M)[{"date":"2020-12-31","value":-12848400000,"profit":false},{"date":"2021-12-31","value":-11082000000,"profit":false},{"date":"2022-12-31","value":-10978300000,"profit":false},{"date":"2023-12-31","value":-10224400000,"profit":false},{"date":"2024-12-31","value":-12687400000,"profit":false}]
EPS (Diluted)(5.92)(4.96)(4.78)(3.73)(3.23)[{"date":"2020-12-31","value":-592,"profit":false},{"date":"2021-12-31","value":-496,"profit":false},{"date":"2022-12-31","value":-478,"profit":false},{"date":"2023-12-31","value":-373,"profit":false},{"date":"2024-12-31","value":-323,"profit":false}]

UroGen Pharma Ltd Ratios

UroGen Pharma Ltd Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

URGN
Cash Ratio 3.01
Current Ratio 3.99
Quick Ratio 3.79

UroGen Pharma Ltd Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

URGN
ROA (LTM) -33.96%
ROE (LTM) -1481.26%

UroGen Pharma Ltd Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

URGN
Debt Ratio Lower is generally better. Negative is bad. 1.62
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.62

UroGen Pharma Ltd Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

URGN
Trailing PE NM
Forward PE NM
P/S (TTM) 9.80
P/B 19.27
Price/FCF NM
EV/R 10.27
EV/Ebitda NM
PEG NM

FAQs

What is UroGen Pharma Ltd share price today?

UroGen Pharma Ltd (URGN) share price today is $20.1

Can Indians buy UroGen Pharma Ltd shares?

Yes, Indians can buy shares of UroGen Pharma Ltd (URGN) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in URGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of UroGen Pharma Ltd be purchased?

Yes, you can purchase fractional shares of UroGen Pharma Ltd (URGN) via the Vested app. You can start investing in UroGen Pharma Ltd (URGN) with a minimum investment of $1.

How to invest in UroGen Pharma Ltd shares from India?

You can invest in shares of UroGen Pharma Ltd (URGN) via Vested in three simple steps:

  • Click on Sign Up or Invest in URGN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in UroGen Pharma Ltd shares
What is UroGen Pharma Ltd 52-week high and low stock price?

The 52-week high price of UroGen Pharma Ltd (URGN) is $30. The 52-week low price of UroGen Pharma Ltd (URGN) is $3.42.

What is UroGen Pharma Ltd price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of UroGen Pharma Ltd (URGN) is

What is UroGen Pharma Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of UroGen Pharma Ltd (URGN) is 19.27

What is UroGen Pharma Ltd dividend yield?

The dividend yield of UroGen Pharma Ltd (URGN) is 0.00%

What is the Market Cap of UroGen Pharma Ltd?

The market capitalization of UroGen Pharma Ltd (URGN) is $946.01M

What is UroGen Pharma Ltd's stock symbol?

The stock symbol (or ticker) of UroGen Pharma Ltd is URGN

How Can Investors Use UroGen Pharma Ltd Share Price Data for Long-Term Investment Decisions?

Consider the share price of UroGen Pharma Ltd as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether UroGen Pharma Ltd has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from UroGen Pharma Ltd shares for Indian investors?

When investing in UroGen Pharma Ltd shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the UroGen Pharma Ltd stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare UroGen Pharma Ltd share price with other stocks in the same sector?

Rather than merely checking the share price of UroGen Pharma Ltd and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that UroGen Pharma Ltd stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top